Chemotherapy-induced cognitive impairment in hematological malignancies

Table 1 Demographic and clinical characteristics of all participants of the study

		Number	Percentage
Diagnosis	AML	45	30.00
	ALL	15	10.00
	CML	16	10.67
	CLL	20	13.33
	MDS	2	1.33
	Lymphoma	25	16.67
	MM	27	18.00
Chemotherapy protocol	Intensified protocol	56	37.33
	TKIs	13	8.67
	Velcade	27	18.00
	Others	54	36.00
Route of administration chemotherapy	Oral	15	10.00
Route of administration chemotherapy	Parenteral	135	90.00
Comorbidities	No comorbidities	104	69.33
	HTN	16	10.67
	DM	10	6.67
	Viral hepatic infection	8	5.33
	More than one	12	8.00
Remission status	Remitted	103	68.67
Remission status	Resistant or refractory	47	31.33

AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, CML chronic myeloid leukemia, CLL chronic lymphocytic leukemia, MDS myelodysplastic syndrome, MM multiple myeloma, TKIs tyrosine kinase inhibitors, HTN hypertension, DM diabetes mellitus. Intensified protocols include the following: 3 + 7, HIDAC, hyper-CVAD, FCR, ABVD, and R-CHOP. Other chemotherapies include the following: low-dose ara-c, 5-azacitidine, CVP, and chlorambucil-based therapy